ClinicalTrials.gg
CompletedNCT05724693Updated Jul 31, 2024

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

A Phase 1 interventional study of Bemnifosbuvir (BEM) in Healthy Volunteer and Hepatic Impairment, sponsored by Atea Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose

02

Conditions studied

  • Healthy Volunteer
  • Hepatic Impairment
03

In context

Lead sponsor

Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must agree to use two methods of from Screening through 90 days after administration of the last dose of study drug
  • Females must have a negative pregnancy test at Screening and prior to dosing
  • of 18.5 to 42.0 kg/m2
  • Willing to comply with the study requirements and to provide written

Subjects with Normal Hepatic Function (Groups 3 and 5):

  • Medically healthy, in the opinion of an Investigator
  • Must match by gender, age (± 10 years), and BMI (± 20%) to the pooled mean values of subjects with hepatic impairment

Hepatic Impaired Subjects (Groups 1, 2, and 4):

  • Considered stable for at least 1 month prior to Screening, as per the judgement of an Investigator
  • When applicable, presence of mild hepatic impairment ( Class A: score of 5 to 6), moderate hepatic impairment (Child-Pugh Class B: score of 7 to 9) or severe hepatic impairment (Child-Pugh Class C: score of 10 to 15). Hepatic impairment should be stable for at least 1 month prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Infected with virus, virus, or COVID-19
  • Abuse of alcohol or drugs
  • Use of other drugs within 28 days of dosing
  • Other medical conditions or laboratory abnormalities

Hepatic Impaired Subjects (Groups 1, 2, and 4):

  • Currently undergoing any method of dialysis
  • History of liver transplant
  • Presence of poorly controlled Type 1 or Type 2 diabetes as defined by (HbA1c) > 10%
  • Evidence of hepatic carcinoma presence at Screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Group 1 -Mild Hepatic Impairment

    Drug: single dose Bemnifosbuvir (BEM)

    Drug: Bemnifosbuvir (BEM)

  • Experimental
    Group 2-Moderate Hepatic Impairment

    Drug: single dose Bemnifosbuvir (BEM)

    Drug: Bemnifosbuvir (BEM)

  • Experimental
    Group 3 - Healthy Subjects matching mild and moderate impairment groups

    Drug: single dose Bemnifosbuvir (BEM)

    Drug: Bemnifosbuvir (BEM)

  • Experimental
    Group 4 - Severe Hepatic Impairment

    Drug: single dose Bemnifosbuvir (BEM)

    Drug: Bemnifosbuvir (BEM)

  • Experimental
    Group 5 - Normal hepatic function matching severe impairment group

    Drug: single dose Bemnifosbuvir (BEM)

    Drug: Bemnifosbuvir (BEM)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)

    Time frame: Day 1

  2. Pharmacokinetics (PK) of BEM Area under the plasma concentration-time curve (AUC)

    Time frame: Day 1

  3. Pharmacokinetics (PK) of BEM AUC

    Time frame: Day 1

07

Study locations

1 site
  • Atea Study Site Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Apr 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2023
First posted
Feb 13, 2023
StartActual
Jan 30, 2023
Primary completionActual
Apr 23, 2024
CompletionActual
Apr 23, 2024
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05724693
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Jan 30, 2023
Primary completion
Apr 23, 2024
Completion
Apr 23, 2024
Last update
Jul 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bemnifosbuvir

Start the discussion